Showing results (181-190 of 260) with videos related to
Sort By:
Pageof 26
Antimicrobial Agents and Chemotherapy|February 23, 2023
Population Pharmacokinetic and Pharmacodynamic Analysis of Valganciclovir for Optimizing Preemptive Therapy of Cytomegalovirus Infections in Kidney Transplant RecipientsPier Giorgio Cojutti, Aaron J Heffernan, Thomas Tängdén, et al.Clinical Pharmacokinetics|November 3, 2025
Population Pharmacokinetics of a Novel Oral Fosfomycin Prophylactic Scheme in the Plasma and Prostate of Patients Undergoing Endoscopic Surgery for Benign Prostatic HyperplasiaPier Giorgio Cojutti, Pasquale Maria Berrino, Valeria Rotaru, et al.Antimicrobial Agents and Chemotherapy|September 22, 2025
Targeting Pseudomonas aeruginosa resistance at the exposure frontier: a population PK/PD blueprint for ceftolozane/tazobactam continuous infusionPier Giorgio Cojutti, Manjunath P Pai, Milo Gatti, et al.Clinical Pharmacokinetics|October 25, 2024
Impact of Continuous Infusion Meropenem PK/PD Target Attainment on C-Reactive Protein Dynamics in Critically Ill Patients With Documented Gram-Negative Hospital-Acquired or Ventilator-Associated PneumoniaCarla Troisi, Pier Giorgio Cojutti, Matteo Rinaldi, et al.Journal of Pharmaceutical and Biomedical Analysis|April 7, 2020
A liquid chromatography-tandem mass spectrometry platform for the routine therapeutic drug monitoring of 14 antibiotics: Application to critically ill pediatric patientsSebastiano Barco, Alessio Mesini, Laura Barbagallo, et al.Antimicrobial Agents and Chemotherapy|October 29, 2025
Keeping the horse with the cart: are we underdosing tazobactam even when using continuous-infusion ceftolozane/tazobactam for effectively preventing resistance development by ESBL-producing Enterobacterales?Manjunath P Pai, Pier Giorgio Cojutti, Milo Gatti, et al.International Journal of Antimicrobial Agents|March 6, 2023
A descriptive case series of the relationship between maintenance of conservative PK/PD efficacy thresholds of dalbavancin over time and clinical outcome in long-term treatment of staphylococcal osteoarticular infectionsMilo Gatti, Pierluigi Viale, Pier Giorgio Cojutti, et al.Antibiotics (Basel, Switzerland)|February 26, 2025
Could a Reduced Dose of 8 g of Continuous Infusion Fosfomycin Be Considered as Effective as and Safer than a Standard 16 g Dose When Combined with High-Dose Daptomycin in the Treatment of Staphylococcal osteoarticular Infections?Pier Giorgio Cojutti, Sara Tedeschi, Eleonora Zamparini, et al.The Journal of Antimicrobial Chemotherapy|March 24, 2025
A pre-post quasi-experimental study of the impact of TDM-guided aggressive pharmacokinetic/pharmacodynamic target attainment of continuous infusion ceftolozane/tazobactam monotherapy in treating severe Pseudomonas aeruginosa infections: a strategy useful for raising the bar?Milo Gatti, Matteo Rinaldi, Cecilia Bonazzetti, et al.Clinical Pharmacokinetics|August 29, 2020
Comparative Population Pharmacokinetics of Darunavir in SARS-CoV-2 Patients vs. HIV Patients: The Role of Interleukin-6Pier Giorgio Cojutti, Angela Londero, Paola Della Siega, et al.Pageof 26